Specifically, polyphenol (-)-epi-gallocatechin-3-gallate (EGCG) is used in both AD and PD cases and acts as an inhibitor of α-synuclein and amyloid beta fibril-maturation, by converting large amyloid fibrils into smaller non-toxic aggregates (Bieschke et al., 2010). This evidence concerns the gene SNCA and Alzheimer disease.